Dr Ivan Koychev, is a Clinical Associate Professor in Neuropsychology at Imperial College in London, and Lead for our FAST study and Great Minds Register:
“Of greatest interest were the trontinemab and USPOINTER results. Trontinemab demonstrated accelerated amyloid clearance, favourable biomarker shifts, and a manageable safety profile at 28 weeks. If the Phase 3 data support these results, it would lead to a change in the duration, safety and general approach to treating early and preclinical AD. U.S. POINTER is the largest lifestyle intervention Alzheimer’s prevention trial in the U.S., confirming the Finnish FINGER findings in a more diverse and representative population. These findings support the emerging concept of “precision prevention”, combining lifestyle and therapeutic strategies tailored to individual risk profiles for maximum impact.”
Professor John Gallacher, Director of Dementias Platform UK
“You can spend a lot of time throughout the year in video calls and exchanging emails. None are real substitutes for getting together to chat, even for a few minutes. There are always ideas you want to share, and here in Toronto it’s been possible to talk about exciting plans for the future: What’s next on the research agenda? How can a collaboration be deepened? How can our team and our world class resources help take a project forward at pace – and scale?”
“With so many industry and academic researchers together this week, it’s hard not to feel optimistic that progress is being made: that our contribution is significant and impactful.”
Professor Sarah Bauermeister, Associate Professor at University of Oxford’s Department of Psychiatry.
I spoke with a friend from the third sector in the UK and we both agree that AAIC just structure their conference really well to be able to do that. Whether it’s the longer lunch breaks, the design of coffee areas, it just facilitate those conversations well. Every day I have met with people and we’ve talked about science, funding and grants.
All of our DPUK researchers here, the postdocs and DPhils have said “Oh, I spoke with this or that professor…they want to collaborate. And these are eminent people in their field standing by their posters. That’s great that everyone is at an equal level here. It is what’s makes AAIC so distinctive. It reinforces the point that without exception, everyone is trying to do good science, collaborate, move forward.
The thing that pleases me most is how much work there is around MCI. Up to now, people have been rather ‘hands off’ because it is often so difficult. There’s no diagnostic plan for MCI and people say it’s so vague or that no one knows how to define it. Yet, this year there are stands here looking at what happens after a diagnosis. And that’s nice to see. People are starting to think what is the next step. How do they get supported.”